Related Experiment Video

Updated: Jul 12, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story

Lecia V Sequist1, Thomas J Lynch

  • 1Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA. lvsequist@partners.org

Annual Review of Medicine
|August 25, 2007
PubMed

Insights

Epidermal growth factor receptor (EGFR) inhibitors have transformed non-small cell lung cancer (NSCLC) treatment. Discovering EGFR mutations predicts patient response to these targeted therapies, guiding future research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) targeted therapies have significantly advanced non-small cell lung cancer (NSCLC) treatment.
  • Understanding the molecular basis of NSCLC has been driven by the development of these therapies.
  • EGFR mutations are key predictors of response to anti-EGFR drugs.

Purpose of the Study:

  • To review the clinical progression of EGFR tyrosine kinase inhibitors.
  • To discuss the identification of molecular markers that predict treatment response.
  • To outline future research avenues in EGFR-targeted NSCLC therapy.

Main Methods:

  • Literature review of clinical trials and molecular studies.
  • Analysis of data on EGFR tyrosine kinase inhibitors' efficacy.
  • Synthesis of findings on molecular predictors of response.

Main Results:

  • EGFR tyrosine kinase inhibitors show significant efficacy in NSCLC patients with specific mutations.
  • Molecular profiling is crucial for identifying patients likely to benefit from anti-EGFR therapy.
  • Continued research is essential for optimizing treatment strategies and overcoming resistance.

Conclusions:

  • Targeted therapy based on EGFR mutation status has revolutionized NSCLC management.
  • Personalized medicine approaches are critical for effective cancer treatment.
  • Further investigation into resistance mechanisms and novel therapeutic strategies is warranted.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...